185 related articles for article (PubMed ID: 12781704)
21. Pharmacology and mechanism of action of forodesine, a T-cell targeted agent.
Gandhi V; Balakrishnan K
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S8-12. PubMed ID: 18086347
[TBL] [Abstract][Full Text] [Related]
22. The effect of deoxyguanosine on human lymphocyte function. II. Analysis of the interference with B lymphocyte differentiation in vitro.
Spaapen LJ; Rijkers GT; Staal GE; Rijksen G; Duran M; Stoop JW; Zegers BJ
J Immunol; 1984 May; 132(5):2318-23. PubMed ID: 6425400
[TBL] [Abstract][Full Text] [Related]
23. Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia.
Balakrishnan K; Ravandi F; Bantia S; Franklin A; Gandhi V
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):458-66. PubMed ID: 23773454
[TBL] [Abstract][Full Text] [Related]
24. The effect of deoxyguanosine on human lymphocyte function. I. Analysis of the interference with lymphocyte proliferation in vitro.
Spaapen LJ; Rijkers GT; Staal GE; Rijksen G; Wadman SK; Stoop JW; Zegers BJ
J Immunol; 1984 May; 132(5):2311-7. PubMed ID: 6425399
[TBL] [Abstract][Full Text] [Related]
25. Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents.
Schramm VL
Biochim Biophys Acta; 2002 Jul; 1587(2-3):107-17. PubMed ID: 12084452
[TBL] [Abstract][Full Text] [Related]
26. Determinants of deoxyadenosine toxicity in hybrids between human T- and B- lymphoblasts as a model for the development of drug resistance in T-cell acute lymphoblastic leukemia.
Kurtzberg J; Hershfield MS
Cancer Res; 1985 Apr; 45(4):1579-86. PubMed ID: 3872167
[TBL] [Abstract][Full Text] [Related]
27. A purine nucleoside phosphorylase (PNP) inhibitor induces apoptosis via caspase-3-like protease activity in MOLT-4 T cells.
Posmantur R; Wang KK; Nath R; Gilbertsen RB
Immunopharmacology; 1997 Oct; 37(2-3):231-44. PubMed ID: 9403342
[TBL] [Abstract][Full Text] [Related]
28. Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies.
Furman RR; Hoelzer D
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S29-34. PubMed ID: 18086344
[TBL] [Abstract][Full Text] [Related]
29. The biochemistry and pharmacology of PD 116124 (8-amino-2'-nordeoxyguanosine), an inhibitor of purine nucleoside phosphorylase (PNP).
Dong MK; Scott ME; Schrier DJ; Suto MJ; Sircar JC; Black A; Chang T; Gilbertsen RB
J Pharmacol Exp Ther; 1992 Jan; 260(1):319-26. PubMed ID: 1530976
[TBL] [Abstract][Full Text] [Related]
30. Mutations induced at the hypoxanthine-guanine phosphoribosyltransferase locus of human T-lymphoblasts by perturbations of purine deoxyribonucleoside triphosphate pools.
Mattano SS; Palella TD; Mitchell BS
Cancer Res; 1990 Aug; 50(15):4566-71. PubMed ID: 2369732
[TBL] [Abstract][Full Text] [Related]
31. New catalytic mechanism for human purine nucleoside phosphorylase.
Canduri F; Fadel V; Basso LA; Palma MS; Santos DS; de Azevedo WF
Biochem Biophys Res Commun; 2005 Feb; 327(3):646-9. PubMed ID: 15649395
[TBL] [Abstract][Full Text] [Related]
32. Glutathione-dependent reduction of arsenate in human erythrocytes--a process independent of purine nucleoside phosphorylase.
Németi B; Gregus Z
Toxicol Sci; 2004 Dec; 82(2):419-28. PubMed ID: 15470234
[TBL] [Abstract][Full Text] [Related]
33. Effects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid cells.
Conry RM; Bantia S; Turner HS; Barlow DL; Allen KO; LoBuglio AF; Montgomery JA; Walsh GM
Immunopharmacology; 1998 Jul; 40(1):1-9. PubMed ID: 9776473
[TBL] [Abstract][Full Text] [Related]
34. Purine deoxynucleoside toxicity in nondividing human lymphoid cells.
Kefford RF; Fox RM
Cancer Res; 1982 Jan; 42(1):324-30. PubMed ID: 6976204
[TBL] [Abstract][Full Text] [Related]
35. Effects of deoxynucleosides on cultured human leukemia cell growth and deoxynucleotide pools.
Ross DD; Akman SA; Schrecker AW; Bachur NR
Cancer Res; 1981 Nov; 41(11 Pt 1):4493-8. PubMed ID: 6975653
[TBL] [Abstract][Full Text] [Related]
36. Mechanism of thiol-supported arsenate reduction mediated by phosphorolytic-arsenolytic enzymes: II. Enzymatic formation of arsenylated products susceptible for reduction to arsenite by thiols.
Gregus Z; Roos G; Geerlings P; Németi B
Toxicol Sci; 2009 Aug; 110(2):282-92. PubMed ID: 19478237
[TBL] [Abstract][Full Text] [Related]
37. Different pathways for deoxyguanosine toxicity in T-lymphocytes of various developmental stages.
Scharenberg JG; Rijkers GT; Spaapen LJ; Toebes EA; Rijksen G; Duran M; Staal GE; Zegers BJ
Int J Immunopharmacol; 1988; 10(6):675-86. PubMed ID: 2974022
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphatein primary human leukemia cells.
Rodriguez CO; Legha JK; Estey E; Keating MJ; Gandhi V
Clin Cancer Res; 1997 Nov; 3(11):2107-13. PubMed ID: 9815603
[TBL] [Abstract][Full Text] [Related]
39. Regulation of thymocyte proliferation and survival by deoxynucleosides. Deoxycytidine produced by thymic accessory cells protects thymocytes from deoxyguanosine toxicity and stimulates their spontaneous proliferation.
Penit C; Papiernik M
Eur J Immunol; 1986 Mar; 16(3):257-63. PubMed ID: 3514238
[TBL] [Abstract][Full Text] [Related]
40. Potentiation of 2'-deoxyguanosine cytotoxicity by a novel inhibitor of purine nucleoside phosphorylase, 8-amino-9-benzylguanine.
Shewach DS; Chern JW; Pillote KE; Townsend LB; Daddona PE
Cancer Res; 1986 Feb; 46(2):519-23. PubMed ID: 3079664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
